All news

AbbVie beats, raises guidance and lifts dividend

Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash

AbbVie posted strong third-quarter 2026 results, raised full-year revenue guidance and lifted its quarterly dividend. Growth rests on immunology, neuroscience and oncology therapies including Skyrizi, Rinvoq and Vraylar, plus an oncology pipeline development with etentamig. Analysts see 23 Buy, 5 Hold and 1 Sell ratings, with a $306.42 target versus $288.24.

Read original source

ABBV company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.